• Pulse Biosciences entered an equity distribution agreement with Mizuho to sell up to USD 75 million of common stock in an at-the-market offering.
• Sales can be made from time to time at prevailing market prices, prices tied to market levels, or negotiated prices.
• Mizuho will act as sales agent, earning up to a 3% commission on gross proceeds from shares sold.
• The program uses the company’s effective Form S-3 shelf registration filed Feb. 19, 2026, effective Feb. 27, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-026351), on August 06, 2026, and is solely responsible for the information contained therein.